LLY

1,066.57

-0.02%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

NVS

150.61

-0.98%↓

LLY

1,066.57

-0.02%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

NVS

150.61

-0.98%↓

LLY

1,066.57

-0.02%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

NVS

150.61

-0.98%↓

LLY

1,066.57

-0.02%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

NVS

150.61

-0.98%↓

LLY

1,066.57

-0.02%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

NVS

150.61

-0.98%↓

Kodu・Aktsiate loetelu・Johnson and Johnson

Johnson and Johnson

Suletud

SektorTervishoid

230.23 -1.85

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

229.1

Max

234.64

Põhinäitajad
By Trading Economics
Sissetulek	119M 5.2B
Müük	-502M 24B
P/E Sektori keskmine	26.526 49.701
Aktsiakasum	2.7
Dividenditootlus	2.29
Kasumimarginaal	21.756
Töötajad	138,200
EBITDA	182M 6.4B

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+13.68% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	2.29% 2.39%
Järgmine tulemuste avaldamine	15. juuli 2026
Järgmine dividendimakse kuupäev	9. juuni 2026
Järgmine aktsia dividendi kuupäev (ex-date)	26. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-22B 551B
Eelmine avamishind	232.08
Eelmine sulgemishind	230.23

Uudiste sentiment

By Acuity

26%

74%

59 / 345 Pingereas Healthcare

Johnson and Johnson Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. apr 2026, 13:27 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson to Acquire Atraverse Medical to Bolster Cardiac Device Portfolio

23. apr 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

22. apr 2026, 11:27 UTC

Tulu

Intuitive Surgical Earnings Show Big Beats Don't Always Spark Stock Rallies -- Barrons.com

14. apr 2026, 19:38 UTC

Tulu

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14. apr 2026, 14:13 UTC

Tulu

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14. apr 2026, 12:57 UTC

Tulu

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14. apr 2026, 11:19 UTC

Tulu

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14. apr 2026, 10:34 UTC

Tulu

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

14. apr 2026, 10:20 UTC

Market Talk

Tulu

J&J Sees Path to Double-Digit Growth by End of Decade -- Market Talk

14. apr 2026, 10:20 UTC

Market Talk

Tulu

J&J's Tremfya Sales Continue to Surge -- Market Talk

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: With MedTech, Anticipate Additional Rounds of VBP in China Throughout Year, Heavier in Second Half of Year >JNJ

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: Expect Heavier Investment in First Half of 2026 Year >JNJ

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: With Innovative Medicine, Expect More Pronounced Sales Impact From Newly Launched Products as 2026 Progresses>JNJ

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson Announce Planned Enterprise Business Review for Dec. 8, 2026 >JNJ

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: Anticipate Higher EPS Growth in Second Half of Year Vs First Half >JNJ

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: With MedTech, Expect Continued Acceleration of Newly Launched Products as Year Progresses With Normalized Seasonality >JNJ

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: With MedTech, Surgery Transformation Sales Headwinds Expected to Increase Through Year >JNJ

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson Sees 2026 Adjusted Operational EPS $11.30-$11.50 Vs Prior View $11.28-$11.48 >JNJ

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: Anticipate Fairly Consistent Operational Sales Growth in First and Second Half With 53rd Week Affecting Second Half >JNJ

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: With Innovative Medicine, Anticipate Generic Competition for Opsumit (Second Half in U.S.) and Simponi (First Half in EU; Potentially Second Half in U. S.) >JNJ

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson Sees 2026 Adj. Operational Sales Growth in Range of 5.6%-6.6% Vs Prior View 5.4%-6.4% >JNJ

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: 1Q Innovative Medicine Operational Sales Growth Driven Primarily by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya and Spravato >JNJ

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson Raises 2026 View To Sales $100.3B-$101.3B Vs Prior View $100B-$101B >JNJ

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson 1Q Orthopaedics Sales $2.38B >JNJ

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: 1Q MedTech Business Growth Driven Primarily by Electrophysiology Products, Abiomed, Shockwave as Well as Trauma >JNJ

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson Sees 2026 Operational Sales of $99.7B-$100.7B Vs Prior View $99.5B-$100.5B>JNJ

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson 1Q Adj EPS $2.70 >JNJ

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: New Treatment for Bladder Cancer Inlexzo Is Outperforming All Recent Launches Based on Unique Patients Treated in First 6 Months of Approval >JNJ

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson 1Q U.S. Sales $13.33B >JNJ

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson 1Q International Sales $10.73B >JNJ

Võrdlus sarnastega

Hinnamuutus

Johnson and Johnson Prognoos

Hinnasiht

By TipRanks

13.68% tõus

12 kuu keskmine prognoos

Keskmine 266.4 USD 13.68%

Kõrge 285 USD

Madal 250 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Johnson and Johnson 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

17 ratings

Osta

Hoia

Müü

Põhineb 17 analüütiku instrumendi Johnson and Johnson aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

59 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.